Copyright
©The Author(s) 2020.
World J Diabetes. Nov 15, 2020; 11(11): 489-500
Published online Nov 15, 2020. doi: 10.4239/wjd.v11.i11.489
Published online Nov 15, 2020. doi: 10.4239/wjd.v11.i11.489
Sudomotor dysfunction (-) | Sudomotor dysfunction (+) | χ2/t/z | P value | |
n | 331 | 135 | - | - |
Male, n (%) | 234 (70.69) | 92 (68.15) | 0.296 | 0.586 |
Age (yr) | 53.30 ± 11.91 | 57.45 ± 13.03 | -3.318 | 0.001 |
Diabetes duration (yr) | 7 (2, 11) | 10 (6, 15) | -4.266 | < 0.001 |
Smoking, n (%) | 84 (25.38) | 65 (48.15) | 22.86 | < 0.001 |
SBP (mmHg) | 132.12 ± 15.82 | 135.30 ± 20.02 | -1.646 | 0.101 |
DBP (mmHg) | 79.46 ± 9.69 | 79.13 ± 10.57 | 0.322 | 0.748 |
BUN (mmol/L) | 5.40 (4.50, 6.63) | 5.90 (4.80, 7.40) | -2.845 | 0.004 |
SCr (µmol/L) | 56.00 (48.00, 67.00) | 60.00 (48.00, 79.00) | -1.703 | 0.089 |
UA (µmol/L) | 328.18 ± 88.92 | 324.04 ± 88.30 | 0.456 | 0.648 |
TC (mmol/L) | 4.35 (3.77, 5.11) | 4.30 (3.55, 5.31) | -0.567 | 0.571 |
TG (mmol/L) | 1.51 (1.04, 2.40) | 1.67 (1.12, 2.52) | -0.856 | 0.392 |
HDL (mmol/L) | 1.03 (0.90, 1.24) | 1.09 (0.91, 1.27) | -1.067 | 0.286 |
LDL (mmol/L) | 2.56 (2.10, 3.25) | 2.48 (1.82, 3.19) | -1.297 | 0.195 |
HbA1c (%) | 8.60 ± 2.01 | 8.94 ± 2.28 | -1.564 | 0.118 |
BMI (kg/m2) | 25.61 ± 3.53 | 25.27 ± 3.82 | 0.899 | 0.369 |
FBG (mmol/L) | 7.23 ± 2.35 | 7.74 ± 2.71 | -1.770 | 0.079 |
PBG (mmol/L) | 15.62 ± 3.63 | 15.92 ± 3.68 | -0.710 | 0.478 |
SD (mmol/L) | 2.25 (1.80, 2.85) | 2.46 (1.89, 3.06) | -2.234 | 0.025 |
MAGE (mmol/L) | 4.38 (3.47, 5.50) | 4.08 (3.62, 5.56) | -0.168 | 0.866 |
MODD (mmol/L) | 1.95 (1.40, 2.67) | 2.28 (1.63, 3.08) | -2.562 | 0.010 |
ADDR (mmol/L) | 21.46 (14.55, 28.02) | 27.37 (15.11, 34.82) | -2.411 | 0.016 |
M value (mmol/L) | 5.99 (3.01, 11.25) | 11.30 (3.85, 24.67) | -4.096 | < 0.001 |
TBR (%) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | -1.093 | 0.274 |
TIR (%) | 72.82 (53.06, 86.79) | 53.12 (28.36, 79.69) | -4.446 | < 0.001 |
TAR (%) | 26.38 (12.65, 42.97) | 44.73 (19.28, 71.20) | -4.602 | < 0.001 |
Microvascular complications | ||||
DN, n (%) | 51 (15.41) | 53 (39.26) | 31.465 | < 0.001 |
DR, n (%) | 69 (20.85) | 62 (45.93) | 29.846 | < 0.001 |
Treatment, n (%) | ||||
No treatment | 27 (8.16) | 7 (5.19) | 7.107 | 0.069 |
OHA | 104 (31.42) | 29 (21.48) | ||
Insulin | 44 (13.29) | 20 (14.81) | ||
OHA and insulin | 156 (47.13) | 79 (58.52) |
- Citation: Guo QY, Lu B, Guo ZH, Feng ZQ, Yuan YY, Jin XG, Zang P, Gu P, Shao JQ. Continuous glucose monitoring defined time-in-range is associated with sudomotor dysfunction in type 2 diabetes. World J Diabetes 2020; 11(11): 489-500
- URL: https://www.wjgnet.com/1948-9358/full/v11/i11/489.htm
- DOI: https://dx.doi.org/10.4239/wjd.v11.i11.489